Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

International journal of oncology

Volumn 18, Issue 5, 2001, Pages 1061-1069

  Agrawal, S ^a   Kandimalla, E R ^a   Yu, D ^a   Hollister, B A ^a   Chen, S F ^a   Dexter, D L ^a   Alford, T L ^a   Hill, B ^a   Bailey, K S ^a   Bono, C P ^a   Knoerzer, D L ^a   Morton, P A ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; IRINOTECAN; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 0035347408     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.18.5.1061     Document Type: Article

References (0)